RCIXLabs offers an AI platform that analyzes historical manufacturing and clinical data to predict the target product profile of T‑cell therapies and identify the critical process parameters that drive key quality attributes. The tool provides data‑driven recommendations and visual dashboards to help biotech firms and CMO partners optimize processes, reduce variability, and improve efficacy and safety outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Developing T‑cell therapies involves complex manufacturing processes where identifying the critical process parameters (CPPs) that affect product quality is difficult, leading to translational gaps between preclinical data and clinical outcomes.
Solution
RCIXLabs provides a biology‑trained AI platform that predicts the target product profile of a T‑cell therapy and links it to the underlying critical quality attributes (CQAs). By analyzing historical manufacturing and clinical data, the machine‑learning model highlights the CPPs most likely to impact efficacy and safety. This unbiased tool enables developers to optimize process steps, reduce variability, and improve response rates in clinical trials, thereby increasing the commercial viability of cell‑based drugs.
Target Audience
Primary customers are biotech companies and contract manufacturing organizations developing autologous or allogeneic T‑cell therapies that require rigorous process optimization and quality control.
Features
- Data‑driven identification of CPPs correlated with specific CQAs for T‑cell products
- Predictive modeling of target product profiles based on historical manufacturing and clinical datasets
- Automated recommendation engine for process adjustments to meet desired efficacy and safety thresholds
- Visualization dashboard that maps process variables to quality outcomes for rapid decision‑making
- Integration capability with existing manufacturing data pipelines and LIMS systems